Business NEWS

RONAN O’CAOIMH to replace BRENDAN FARRELL at Trinity Biotech plc

By Amarendra Bhushan for CEOWORLD Magazine Updated:October 6, 2008

RONAN O’CAOIMH to replace BRENDAN FARRELL at Trinity Biotech plc

Since its formation in 1992, Trinity Biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. A combination of strong organic growth and a progressive acquisition-led strategy has seen the company assemble an impressive portfolio of over 500 products to date..

Trinity Biotech plc , a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that Mr. Ronan O’Caoimh, Executive Chairman, has agreed to resume the role of CEO. Mr. O’Caoimh will succeed Mr. Brendan Farrell, who has resigned with immediate effect, having served as Trinity Biotech’s President since 1994 and as CEO since November 2007. Ronan O’Caoimh commented, “I am hugely excited by this challenge and, given our product offering and development pipeline, am determined to deliver on our enormous potential for enhanced shareholder value.”

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company’s website: www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission.

In another news, Trinity Biotech plc , a leading developer and manufacturer of diagnostic
products for the point-of-care and clinical laboratory markets, today announced that Rory Nealon, Chief Operating Officer will present at the William Blair & Co. Small-Cap Growth Stock Conference

RONAN O’CAOIMH
CHIEF EXECUTIVE OFFICER

CHIEF EXECUTIVE OFFICER, co-founded Trinity Biotech in 1992 and acted as CFO until 1994 when he became CEO. Prior to joining Trinity, Mr. O’Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr. O’Caoimh holds a Bachelor of Commerce degree from University College, Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

BRENDAN FARRELL

joined Trinity Biotech in 1994. He was previously Marketing Director of B.M. Browne Limited, a company involved in the marketing and distribution of medical and diagnostic products. Prior to that he was CEO of Noctech Limited, following six years with Baxter Healthcare where he was Director of European Business Development. Mr Farrell has a Masters degree in Biochemistry from University College Cork.

RORY NEALON

CHIEF OPERATING OFFICER, joined Trinity Biotech in early 2003 from Conduit plc, a telecom services company where he was CFO. Previously Mr.Nealon was employed by Allied Irish Banks plc where he invested equity and short-term mezzaine finance into emerging growth companies. Mr. Nealon holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, the Institute of Taxation in Ireland and the U.K. Institute of Corporate Treasurers.

Like this article! ‹ Siemens Agrees to Buy SG Wasseraufbereitung und Regenerierstation GmbH (SG Water) Neal L. Wolkoff to become CEO to ELX Electronic Liquidity Exchange ›
Share this Post: Get It Delivered To Your Inbox